Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Other Accumulated Expenses (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Other Accumulated Expenses for 10 consecutive years, with $7.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 65.0% to $7.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.0 million, a 65.0% decrease, with the full-year FY2025 number at $7.0 million, down 65.0% from a year prior.
  • Other Accumulated Expenses was $7.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $19.0 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $59.9 million in Q3 2022 to a low of $2.6 million in Q2 2025.
  • A 5-year average of $33.8 million and a median of $36.6 million in 2021 define the central range for Other Accumulated Expenses.
  • Biggest YoY gain for Other Accumulated Expenses was 291.95% in 2025; the steepest drop was 91.12% in 2025.
  • Ultragenyx Pharmaceutical's Other Accumulated Expenses stood at $42.1 million in 2021, then grew by 23.99% to $52.2 million in 2022, then tumbled by 40.22% to $31.2 million in 2023, then crashed by 35.89% to $20.0 million in 2024, then crashed by 65.0% to $7.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Other Accumulated Expenses are $7.0 million (Q4 2025), $19.0 million (Q3 2025), and $2.6 million (Q2 2025).